Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings.: Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.

Jonathan Douxfils; Jean-Michel Foidart; Ulysse Gaspard; Guillaume Chatel; Mélanie Taziaux; Maud Jost; Céline Gérard; Laure Morimont

doi:10.5114/pm.2023.128815

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.

Jonathan Douxfils
, Jean-Michel Foidart
, Ulysse Gaspard
, Guillaume Chatel
, Mélanie Taziaux
, Maud Jost
, Céline Gérard
, Laure Morimont

Research output: Contribution to journal › Article › peer-review

48 Downloads (Pure)

Original language	English
Pages (from-to)	117-119
Number of pages	3
Journal	Przeglad menopauzalny = Menopause review
Volume	22
Issue number	2
DOIs	https://doi.org/10.5114/pm.2023.128815
Publication status	Published - Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 5 Gender Equality

Access to Document

10.5114/pm.2023.128815

9663-2023-DouxfilsFinal published version, 150 KB

Cite this

Douxfils, J., Foidart, J.-M., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., & Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Przeglad menopauzalny = Menopause review, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815

Douxfils, Jonathan ; Foidart, Jean-Michel ; Gaspard, Ulysse et al. / Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. In: Przeglad menopauzalny = Menopause review. 2023 ; Vol. 22, No. 2. pp. 117-119.

@article{9f6d859831034140a19e75f946d788c8,

title = "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings.: Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.",

author = "Jonathan Douxfils and Jean-Michel Foidart and Ulysse Gaspard and Guillaume Chatel and M{\'e}lanie Taziaux and Maud Jost and C{\'e}line G{\'e}rard and Laure Morimont",

year = "2023",

month = jun,

doi = "10.5114/pm.2023.128815",

language = "English",

volume = "22",

pages = "117--119",

journal = "Przeglad menopauzalny = Menopause review",

issn = "1643-8876",

publisher = "Termedia Publishing House Ltd.",

number = "2",

}

Douxfils, J, Foidart, J-M, Gaspard, U, Chatel, G, Taziaux, M, Jost, M, Gérard, C & Morimont, L 2023, 'Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.', Przeglad menopauzalny = Menopause review, vol. 22, no. 2, pp. 117-119. https://doi.org/10.5114/pm.2023.128815

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. / Douxfils, Jonathan; Foidart, Jean-Michel; Gaspard, Ulysse et al.
In: Przeglad menopauzalny = Menopause review, Vol. 22, No. 2, 06.2023, p. 117-119.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings.

T2 - Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.

AU - Douxfils, Jonathan

AU - Foidart, Jean-Michel

AU - Gaspard, Ulysse

AU - Chatel, Guillaume

AU - Taziaux, Mélanie

AU - Jost, Maud

AU - Gérard, Céline

AU - Morimont, Laure

PY - 2023/6

Y1 - 2023/6

UR - https://www.scopus.com/pages/publications/85171192980

U2 - 10.5114/pm.2023.128815

DO - 10.5114/pm.2023.128815

M3 - Article

C2 - 37674929

SN - 1643-8876

VL - 22

SP - 117

EP - 119

JO - Przeglad menopauzalny = Menopause review

JF - Przeglad menopauzalny = Menopause review

IS - 2

ER -

Douxfils J, Foidart JM, Gaspard U, Chatel G, Taziaux M, Jost M et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Przeglad menopauzalny = Menopause review. 2023 Jun;22(2):117-119. doi: 10.5114/pm.2023.128815

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.

UN SDGs

Access to Document

Other files and links

Clinical Pharmacology Research Group

The HIC Project : Evaluation of hormone-induced coagulopathy

Cite this

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy.

UN SDGs

Access to Document

Other files and links

Projects

Clinical Pharmacology Research Group

The HIC Project : Evaluation of hormone-induced coagulopathy

Cite this